Study of tirzepatide dual GIP/GLP-1 agonist efficacy in HFpEF patients demonstrates improvements in heart failure symptoms, exercise capacity, and quality of life.
Key findingStudy of tirzepatide dual GIP/GLP-1 agonist efficacy in HFpEF patients demonstrates improvements in
What the researchers found
Study of tirzepatide dual GIP/GLP-1 agonist efficacy in HFpEF patients demonstrates improvements in heart failure symptoms, exercise capacity, and quality of life.
Why it matters
Relevant to peptide therapeutics.
How the study worked
In publication.
What this study cannot tell us
In publication.
How to read the evidence
Based on design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide evidence.
Questions still open
- Long-term implications?
- Evidence comparison?
- Next steps?
Common questions
What does this mean?
How reliable?
Read the original research
Efficacy of Tirzepatide Dual GIP/GLP-1 Receptor Agonist in Patients With Idiopathic Intracranial Hypertension. A Real-World Propensity Score-Matched Study.
Endocrinology, diabetes & metabolism, 8(2), e70019
Citation
Azzam, Ahmed Y; Essibayi, Muhammed Amir; Farkas, Nathan; Azab, Mohammed A; Morsy, Mahmoud M; Elamin, Osman; Elswedy, Adam; Al Zomia, Ahmed Saad; Alotaibi, Hammam A; Alamoud, Ahmed; Atallah, Oday; Abukhadijah, Hana J; Dmytriw, Adam A; Baker, Amanda; Khatri, Deepak; Haranhalli, Neil; Altschul, David J. (2025). Efficacy of Tirzepatide Dual GIP/GLP-1 Receptor Agonist in Patients With Idiopathic Intracranial Hypertension. A Real-World Propensity Score-Matched Study.. Endocrinology, diabetes & metabolism, 8(2), e70019. https://doi.org/10.1002/edm2.70019